Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ETNB

ETNB - 89bio Inc Stock Price, Fair Value and News

8.18USD-0.75 (-8.40%)Market Closed

Market Summary

ETNB
USD8.18-0.75
Market Closed
-8.40%

ETNB Stock Price

View Fullscreen

ETNB RSI Chart

ETNB Valuation

Market Cap

878.6M

Price/Earnings (Trailing)

-5.32

Price/Sales (Trailing)

414.63

EV/EBITDA

-4.34

Price/Free Cashflow

-6.33

ETNB Price/Sales (Trailing)

ETNB Profitability

EBT Margin

-7443.16%

Return on Equity

-32.33%

Return on Assets

-28.59%

Free Cashflow Yield

-15.8%

ETNB Fundamentals

ETNB Revenue

Revenue (TTM)

2.2M

ETNB Earnings

Earnings (TTM)

-165.0M

Earnings Growth (Yr)

-79.22%

Earnings Growth (Qtr)

-28.45%

Breaking Down ETNB Revenue

Last 7 days

-2.8%

Last 30 days

-4.0%

Last 90 days

-15.6%

Trailing 12 Months

-46.9%

How does ETNB drawdown profile look like?

ETNB Financial Health

Current Ratio

15.03

Debt/Equity

0.05

Debt/Cashflow

-6.02

ETNB Investor Care

Shares Dilution (1Y)

35.02%

Diluted EPS (TTM)

-2.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2022652.0K1.2M1.7M2.2M
2021000148.0K

Tracking the Latest Insider Buys and Sells of 89bio Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 11, 2024
ra capital management, l.p.
acquired
7,500,000
5.325
1,408,450
-
Apr 01, 2024
palekar rohan
sold
-575,153
10.91
-52,718
chief executive officer
Apr 01, 2024
palekar rohan
acquired
48,250
1.93
25,000
chief executive officer
Mar 04, 2024
ra capital management, l.p.
bought
20,722,500
15.35
1,350,000
-
Feb 26, 2024
palekar rohan
sold
-48,172
10.76
-4,477
chief executive officer
Feb 17, 2024
mansbach harry h
sold (taxes)
-10,188
9.74
-1,046
chief medical officer
Feb 17, 2024
martins ryan
sold (taxes)
-7,577
9.74
-778
chief financial officer
Feb 17, 2024
le-nguyen quoc
sold (taxes)
-10,188
9.74
-1,046
see remarks
Feb 17, 2024
palekar rohan
sold (taxes)
-44,823
9.74
-4,602
chief executive officer
Feb 09, 2024
palekar rohan
sold (taxes)
-107,062
8.45
-12,670
chief executive officer

1–10 of 50

Which funds bought or sold ETNB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
104
110,356
208,356
0.03%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-0.2
33,609
873,023
-%
May 16, 2024
COMERICA BANK
added
9.66
248,702
1,990,440
0.01%
May 16, 2024
JANE STREET GROUP, LLC
added
29.26
346,064
1,343,510
-%
May 15, 2024
Virtus ETF Advisers LLC
reduced
-6.4
-2,366
93,562
0.05%
May 15, 2024
SPHERA FUNDS MANAGEMENT LTD.
added
26.23
1,439,980
6,004,870
0.84%
May 15, 2024
GREENWOOD GEARHART INC
sold off
-100
-6,445
-
-%
May 15, 2024
Alyeska Investment Group, L.P.
reduced
-48.56
-3,022,200
3,492,000
0.02%
May 15, 2024
Bridgefront Capital, LLC
new
-
165,998
165,998
0.13%
May 15, 2024
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)
reduced
-54.52
-464,670
418,598
0.03%

1–10 of 43

Are Funds Buying or Selling ETNB?

Are funds buying ETNB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ETNB
No. of Funds

Unveiling 89bio Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 06, 2024
ra capital management, l.p.
14.8%
14,254,298
SC 13D/A
Feb 14, 2024
deep track capital, lp
2.10%
2e+06
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
4.2%
3,973,784
SC 13G/A
Feb 14, 2024
cormorant asset management, lp
0.00%
0
SC 13G/A
Feb 14, 2024
rtw investments, lp
6.0%
5,578,931
SC 13G
Feb 13, 2024
suvretta capital management, llc
5.2%
4,888,434
SC 13G/A
Feb 12, 2024
janus henderson group plc
10.8%
10,081,258
SC 13G/A
Feb 12, 2024
janus henderson group plc
9.6%
8,915,141
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
4.48%
4,225,000
SC 13G/A
Jan 29, 2024
blackrock inc.
5.9%
5,454,196
SC 13G

Recent SEC filings of 89bio Inc

View All Filings
Date Filed Form Type Document
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
May 03, 2024
4
Insider Trading
Apr 23, 2024
3
Insider Trading
Apr 19, 2024
ARS
ARS
Apr 17, 2024
DEFA14A
DEFA14A
Apr 17, 2024
DEF 14A
DEF 14A
Apr 17, 2024
8-K
Current Report
Apr 15, 2024
4
Insider Trading
Apr 10, 2024
8-K
Current Report

Peers (Alternatives to 89bio Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

89bio Inc News

Latest updates
Seeking Alpha10 hours ago
Defense World20 May 202408:13 am
Yahoo Finance03 Apr 202407:00 am
The Motley Fool7 months ago

89bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Operating Expenses-6.2%25,362,00027,041,00024,738,00025,108,00026,241,000
  S&GA Expenses30.0%6,298,0004,844,0005,052,0005,259,0005,262,000
  R&D Expenses-14.1%19,064,00022,197,00019,686,00019,849,00020,979,000
EBITDA Margin25.6%-46.22-62.12-90.51-153-604
Interest Expenses1.9%545,000535,000434,000408,000-
Income Taxes700.0%16,0002,000-1,000-
Earnings Before Taxes8.3%-24,586,000-26,803,000-25,054,000-25,564,000-26,435,000
EBT Margin24.7%-47.14-62.56-91.16-154-609
Net Income8.2%-24,602,000-26,805,000-25,054,000-25,565,000-26,288,000
Net Income Margin24.5%-47.15-62.48-91.03-154-608
Free Cashflow-82.9%-27,098,000-14,815,000-14,834,000-24,350,000-28,267,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Assets-3.2%57759646049349419720114813616216818219921122377.0088.0096.0018.0011.00
  Current Assets-3.2%57559446049249419620014713516216718119821022375.0087.0095.0017.0011.00
    Cash Equivalents-31.2%21831625224535155.0072.0061.0055.0052.0040.0036.0068.0098.0014268.0086.0093.0016.0011.00
  Net PPE-19.6%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities11.4%67.0060.0050.0051.0048.0045.0048.0067.0033.0036.0021.009.00-8.00------
  Current Liabilities29.1%38.0030.0025.0026.0024.0025.0034.0027.0018.0020.0020.008.008.008.009.007.008.006.0023.004.00
  Long Term Debt-7.0%23.0025.0025.0024.0024.0020.0013.0012.0014.0017.001.001.00--------
    LT Debt, Current-2.00-----7.008.005.003.00----------
    LT Debt, Non Current-100.0%-25.0025.0024.0024.0020.0013.0012.0014.0017.001.001.00--------
Shareholder's Equity-4.8%51153641044244615215380.0010312614717319020321470.0080.0090.00--
  Retained Earnings-11.3%-509-457-417-382-344-315-290-263-238-213-186-158-137-123-110-95.91-84.14-73.60-54.31-16.18
  Additional Paid-In Capital-100.0%-9938288257904674443443423393343313283263251661641640.000.00
Shares Outstanding2.1%95.0093.0076.0074.0053.0051.0029.0020.0020.0020.0020.0020.00--------
Float----1,176---30.00---166---72,707,052----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-15.8%-39,720-34,293-30,361-34,447-30,085-27,096-14,815-14,835-24,344-28,240-13,450-20,109-14,982-14,028-12,940-11,524-7,752-11,132-6,197-3,964-4,167
  Share Based Compensation23.8%4,9984,0374,3814,1373,5512,7582,5002,5862,5122,1542,3142,4171,7931,2501,15491049316611276.0035.00
Cashflow From Investing-25.5%-79,898-63,64338,326-101,8084,106-11,061-42,058-7,59626,77219,08617,359-13,876-15,410-29,028-71,999-5,744-61.00-111-8.00-18.00-2.00
Cashflow From Financing-87.0%21,030162,171-1,48030,766321,65421,01168,63128,16029.0021,89172.001,692216-312158,292-65.009.0088,377488--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ETNB Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 47,428$ 22,306
General and administrative9,8496,218
Total operating expenses57,27728,524
Loss from operations(57,277)(28,524)
Interest expense(863)(2,075)
Interest income and other, net6,5561,763
Net loss before income tax(51,584)(28,836)
Income tax expense(97)0
Net loss(51,681)(28,836)
Other comprehensive (loss) income:  
Unrealized (loss) gain on marketable securities(714)114
Foreign currency translation adjustments5(4)
Total other comprehensive (loss) income(709)110
Comprehensive loss$ (52,390)$ (28,726)
Net loss per share, basic$ (0.54)$ (0.54)
Net loss per share, diluted$ (0.54)$ (0.54)
Weighted-average shares used to compute net loss per share, basic95,846,74053,171,370
Weighted-average shares used to compute net loss per share, diluted95,846,74053,171,370

ETNB Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 217,573$ 316,161
Marketable securities344,715262,709
Prepaid and other current assets12,49414,664
Total current assets574,782593,534
Operating lease right-of-use assets2,1182,293
Property and equipment, net3746
Other assets385396
Total assets577,322596,269
Current liabilities:  
Accounts payable15,3528,585
Accrued expenses20,29520,530
Operating lease liabilities, current702496
Term loan, current1,8920
Total current liabilities38,24129,611
Operating lease liability, non-current1,6401,817
Term loan, noncurrent, net23,06524,795
Other noncurrent liabilities3,8373,740
Total liabilities66,78359,963
Commitments and contingencies (Note 5)
Stockholders’ equity:  
Common stock, $0.001 par value: 200,000,000 shares authorized; 95,199,724 and 93,269,377 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively9593
Additional paid-in capital1,020,076993,455
Accumulated other comprehensive (loss) income(519)190
Accumulated deficit(509,113)(457,432)
Total stockholders’ equity510,539536,306
Total liabilities and stockholders’ equity$ 577,322$ 596,269
ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
 CEO
 WEBSITE89bio.com
 INDUSTRYBiotechnology
 EMPLOYEES45

89bio Inc Frequently Asked Questions


What is the ticker symbol for 89bio Inc? What does ETNB stand for in stocks?

ETNB is the stock ticker symbol of 89bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 89bio Inc (ETNB)?

As of Wed May 22 2024, market cap of 89bio Inc is 878.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ETNB stock?

You can check ETNB's fair value in chart for subscribers.

What is the fair value of ETNB stock?

You can check ETNB's fair value in chart for subscribers. The fair value of 89bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 89bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ETNB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 89bio Inc a good stock to buy?

The fair value guage provides a quick view whether ETNB is over valued or under valued. Whether 89bio Inc is cheap or expensive depends on the assumptions which impact 89bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ETNB.

What is 89bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, ETNB's PE ratio (Price to Earnings) is -5.32 and Price to Sales (PS) ratio is 414.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ETNB PE ratio will change depending on the future growth rate expectations of investors.